Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies.

Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group.

According to the US immuno-oncology company, ELI-002 targets all the seven KRAS mutations that are behind 99% of all mKRAS-driven cancers, which are estimated to amount to 25% of all human solid tumors.

The AMP KRAS vaccine has gone through preclinical validation, IND-enabling GLP toxicology studies, GMP manufacturing, and also a pre-IND meeting with the FDA.

Elicio raises $33m to advance ELI-002 vaccine and other lymph node-targeted immuno-therapies

Elicio Therapeutics revealed plans to start an initial patient study in pancreatic cancer patients in H1 2020.  The early-stage trials will be multi-site, randomized, controlled studies with initial ELI-002 pancreatic cancer patient data expected to be released in H2 2020.

Robert Connelly – CEO of Elicio Therapeutics said: “We believe ELI-002 can become a universal mKRAS vaccine with the potential to treat and prevent disease recurrence for hundreds of thousands of patients with mKRAS-driven cancers, including pancreatic, colorectal and lung cancer.

“This new funding is a strong endorsement of this program, the Amphiphile platform, and our progress.”

Related posts

• Icosavax, a new vaccine development company, launched in Seattle (0)
• Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD (0)
• Vascular Perfusion to advance organ transportation through ULiSSES device (0)
• Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment (0)
• Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal (0)
• Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials (0)
• Progenity buys assets of ingestible device company Medimetrics (0)
• Constellation doses first patient in phase 1 trial of CPI-0209 for cancer (0)
• Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors (0)
• Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome (0)

The post Elicio raises $33m to advance lymph node-targeted immuno-therapies appeared first on PharmaNewsDaily.com.